| __timestamp | Incyte Corporation | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 165772000 | 1213000 |
| Thursday, January 1, 2015 | 196614000 | 3425000 |
| Friday, January 1, 2016 | 303251000 | 6311000 |
| Sunday, January 1, 2017 | 366406000 | 9518000 |
| Monday, January 1, 2018 | 434407000 | 28080000 |
| Tuesday, January 1, 2019 | 468711000 | 36550000 |
| Wednesday, January 1, 2020 | 516922000 | 46125000 |
| Friday, January 1, 2021 | 739560000 | 68486000 |
| Saturday, January 1, 2022 | 1002140000 | 92032000 |
| Sunday, January 1, 2023 | 1161300000 | 117532000 |
| Monday, January 1, 2024 | 1242157000 |
Unlocking the unknown
In the competitive landscape of biotechnology, effective cost management is crucial. Incyte Corporation and Rhythm Pharmaceuticals, Inc. offer a compelling study in contrasts over the past decade. From 2014 to 2023, Incyte's Selling, General, and Administrative (SG&A) expenses surged by over 600%, reflecting its aggressive growth strategy. In 2023, Incyte's SG&A expenses reached a peak, accounting for nearly 90% of the total expenses between the two companies.
Conversely, Rhythm Pharmaceuticals, Inc. exhibited a more measured increase, with SG&A expenses growing by approximately 9,600% over the same period. This dramatic rise, from a modest base, underscores Rhythm's strategic investments in scaling operations. The data highlights the distinct paths these companies have taken in managing operational costs, offering valuable insights into their strategic priorities and market positioning.
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Incyte Corporation vs Pharming Group N.V.
SG&A Efficiency Analysis: Comparing Incyte Corporation and ADMA Biologics, Inc.
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Rhythm Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc.
Rhythm Pharmaceuticals, Inc. or Arrowhead Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.